SocialPicks Sentiment:
** v.s.
other stocks
|
This Quarter's Sentiment:
|
|
|
IBB Analysis & Videos »
IBB: Bull or Bear?
iShares Nasdaq Biotechnology Index Fund (Consolidated Issue listed on NASDAQ Global Market)
IBB
|
|
|
-0.83%
in
9 days
iShares Nasdaq Biotechnology Index Fund (the Fund) seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index consists of securities of NASDAQ-listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, and which also meet other eligibility criteria. The Index is one of the eight sub-indices of the NASDAQ Composite, which measures all common stocks listed on The NASDAQ Stock Market, Inc. The Fund invests in a representative sample of ...
|
New Indexes to Track Healthcare Trends and More
IBB
|
|
|
-0.62%
in
79 days
<font> Below are links and descriptions for stock indexes I have created, revised, and tracked over the past few years which are now featured at the website Investars YOU. This site includes automated index tracking and allows investors to link their brokerage accounts to create custom stock portfolios based on their individual preferences from the stock indexes at the site. </font> <font> http://www.mikehavrx.com/2009/09/new-indexes-to-track-healthc... </font> <> <font> However, unregistered users have the ability to generate stock ideas from any of the free indexes (including...
|
The best ETFs for betting on biotech
IBB
+2.58%
in
106 days
Filed under: Newsletters, Stocks to Buy "I'm always looking for market leadership; right now, biotechnology stocks are moving up faster than most anything else," says Ron Rowland. In Money & Markets, he eyes biotech ETFs. "Biotechnology is a fascinating sector, one that's made (and lost) a lot of money for millions of investors in recent decades. That's why, in my opinion, you should become familiar with this industry. "Broadly speaking, it's the application of technology to biological materials - plants, animals and people. <>"Nowadays a lot of biotechnology involves manipulating genetic materia...
|
Biotech ETFs: Best bets on health care reform
IBB
+10.67%
in
32 days
(closed on 08/11/09)
Filed under: Newsletters, ETF Investing, Stocks to Buy, Obama Picks  "Health care reform could mean opportunities for astute investors," says Brandon Clay in his Invest With an Edge.
Here, eyes two biotech ETFs that "should be on everyone's watch list." The advisor notes, "With health care on the front burner in Washington, these biotechnology ETFs may finally be ready to pop." "Investors in health care should think outside the realm of traditional pharmaceutical companies and health insurers. Those sectors are each facing headwinds that make stock picking difficult. <>"In addition, several big ph...
|
Lixte Biotech: Shifting Focus to Cancer Drug Discovery
IBB
|
|
|
+9.92%
in
84 days
(closed on 06/26/09)
Lixte Biotechnology (LIXT.OB) was founded as a diagnostics company in 2005 evaluating biomarkers (indicators of disease at the molecular level), but has shifted its focus to become a cancer drug discovery operation. <> Lixte engages in the discovery of anti-cancer compounds to improve the treatment of malignancies with few effective treatment options, such as certain types of brain cancer. Other areas of early-stage, preclinical drug discovery include: (1) improved anti-fungal treatments for patients with compromised immunity (e.g. HIV/AIDS, bone marrow transplantation); (2) neu...
|
BioMedReports.com: Contributing Authors Wanted
IBB
|
|
|
+3.22%
in
18 days
(closed on 04/03/09)
We are looking for contributing authors to submit articles for publication at BioMedReports.com; so if you are interested please contact me or use the online article submission link below: <> Currently, there is no monetary compensation for articles which are chosen for publication, but this may change in the future as our site grows and we may choose to pay the top contributing authors on a freelance basis per published article. Along with your first article submission, please include yo...
|
New Website for Healthcare Investors and Traders
IBB
|
|
|
-15.21%
in
38 days
(closed on 03/16/09)
<> Stay tuned for more details and web links for a new website for healthcare investors and traders, which is designed to provide users with more features beyond my current blog format.
The new site will feature its own blog, discussion forum, news feeds, videos, stock commentaries (including multiple contributors), and other unique content – including my FDA and Clinical Trial Calendars plus a database that includes hundreds of U.S.-listed stocks in the healthcare sector which are organized into unique indexes such as the Emerging Stem Cell Ind< />< /><><><>< />< /><>< />< /><><>< />< /><><>< />< />< />< /><>< /><>< /><>< /><>< /><>< /><>< /><>< /><>< /><>< /><>< /><>< /><>< /><>< /><><>...
|
One Year Analysis of Healthcare ETFs
IBB
|
|
|
+9.76%
in
15 days
(closed on 02/06/09)
<> The table at my website link below includes a summary and statistics for the 25 healthcare exchange-traded funds (ETFs) which are currently on the market. The group posted a 23.5% loss over the past year on an equal-weight basis with an average of about $400M in net assets. However, the top eight ETFs by net assets account for 88.5% of all net assets for the entire group of 25, including Healthcare Sector SPDR (XLV), Pharma HOLDRs (PPH), iShares Nasdaq Biotech (IBB), Biotech HOLDRs (BBH), iShares Dow Jones U.S. Healthcare (IYH), iShares S&P Global Healthcare (IXJ), Vanguard Healthcare (VHT...
|
ETF Innovators: 24 New Product Ideas
IBB
|
|
|
-3.72%
in
5 days
(closed on 01/22/09)
ETF Innovators: 24 New Product Ideas Below are 24 new exchange-traded product (ETP) ideas, which are organized by the following sectors and themes: transports (six), healthcare (11), Non-Healthcare (five), and commodities (two). The 20 stock-based ETF ideas below are structured as semi-active indexes with monthly rebalancing to choose the top rated stocks as active components on an equal-weight basis. <> Most of the ideas represent first-to-market ideas and several such as Air and...
|
Obama-Care Focused on Preventive Medicine
IBB
|
|
|
+1.20%
in
72 days
(closed on 01/17/09)
<> 
In addition to bullish outlooks for generic drugs and Health IT , President-Elect Obama's healthcare plan plans to focus on public health initiatives and mandated coverage of preventive services such as cancer screenings. The accompanying table presents statistics and the top five rated companies in the ETFI Preventive Medicine Index, including vaccine makers such as Emergent BioSolutions (EBS), diabetes care companies such as Novo Nordisk (NVO), diagnostic companies such as Sequenom (SQNM) and Myriad Geneti...
|
Healthcare ETFs Outpace the Market
IBB
|
|
|
-1.72%
in
4 days
(closed on 11/05/08)
<> 
The accompanying table presents an analysis and statistics for the 28 healthcare ETFs listed at the Yahoo! Finance ETF Center. As a group, the healthcare ETFs outpaced the overall market in the past year by more than 10%, posting an average loss of 26.5% compared to a loss of 37.4% for the S&P 500 SPDR ETF (SPY). The best performing healthcare ETF was the Biotech HOLDRs (BBH), thanks to a buyout bid for top holding Genetech (DNA) and solid earnings results this year for the number two position, Amgen (AMGN).
The top three...
|
Biogen Reports Another PML Case in Tysabri Patient
IBB
|
|
|
+4.65%
in
3 days
(closed on 11/01/08)
<> 
After the market close, Biogen (BIIB) filed an 8-K with the SEC reporting a new case of the potentially fatal brain disease known as PML or progressive multifocal leukoencephalopathy in a patient receiving their multiple sclerosis [MS] drug Tysabri, adding to the two new cases which were reported previously in July. Biogen is currently trading down by about 15% after hours while marketing partner Elan (ELN) is down by about 25% as of 5:15 PM. The news adds more uncertainty to Tysabri, which was removed from th...
|
Biotech Blues: Four Stocks on Sale with Hope
IBB
|
|
|
+7.08%
in
4 days
(closed on 10/29/08)
<> The following group of biotech companies have market caps of at least $300M with a one year stock price change that is below the iShares Nasdaq Biotech ETF (IBB) loss of 21.8% (Source: Google Finance, 10/25/08) with potential upside catalysts over the next year.
Alnylam Pharma (ALNY): $872M, -31.6%
Biogen Idec (BIIB): $12B, -48.4%
BioMarin Pharma (BMRN): $1.7B, -33%
Momenta Pharma (MNTA): $348M, -23.4%
Momenta and Novartis (NVS) expect to launch a generic version (M-Enoxaparin) of the injectable...
|
An Earnings Encore for Amgen?
IBB
|
|
|
-6.60%
in
3 days
(closed on 10/25/08)
<> 
I think Amgen (AMGN) will beat consensus estimates for sales and profits again today when it reports after the market close, continuing the same trends as last quarter, including better than expected sales of embattled anemia drugs Aranesp and Epogen. Amgen reported 2Q08 results (see conference call transcript ) that beat consensus analyst estimates and raised its full-year [FY] guidance for earnings and revenue, thanks to much stronger-than-expected sales of its anemia drugs Aranesp and Epogen:
- 2Q08 Revenue +1% at $3.8 bi...
|
People Bullish on IBB
People Bearish on IBB
|
ROCK-STAR INVESTORS
|
|
POPULAR STOCKS
|
|
TODAY'S HEADLINES
|
|
TODAY'S TOP PICKS
|
|
|
More Resources
|
About iShares Nasdaq Biotechnology Index Fund
- Answers.com
